BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
BMY upcoming catalysts
Bristol-Myers Squibb: 5 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 19 readout(s) and 6 FDA event(s). Subscribe to BMY (.ics).
Drugs: Nivolumab, Deucravacitinib, Dexamethasone, Ipilimumab, Cisplatin, KarXT, BMS-986435, BMS-986446, BMS-986470, Famotidine, Pantoprazole, Carboplatin, Paclitaxel, Pemetrexed, Repotrectinib, Crizotinib, Tazemetostat, Trametinib, Mezigdomide, Carfilzomib, Bevacizumab, Sorafenib, lenvatinib, Elotuzumab, Lenalidomide, Bortezomib, Pomalidomide, Gemcitabine
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-14 est. | P2 | Bristol-Myers Squibb BMY | NCT06122779 Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure | active not recruiting | 227 |
| 2026-12-17 est. | P2 | Bristol-Myers Squibb BMY | NCT06268886 Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | Alzheimer Disease, Early Onset | active not recruiting | 310 |
| 2027-01-06 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT06481306 A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease | Anemia, Sickle Cell; Healthy Volunteers | recruiting | 224 |
| 2027-02-05 est. | P2 | Bristol-Myers Squibb BMY | NCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Un | Non-Small Cell Lung Cancer | active not recruiting | 76 |
| 2027-02-16 est. | P3 | Bristol-Myers Squibb BMY | NCT06140836 A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cel | Carcinoma, Non-Small-Cell Lung | active not recruiting | 190 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-09-30 | FDA approval | approved | BRISTOL BMY | CAMZYOS | Approved 2026-09-30: CAMZYOS (NDA214998 SUPPL13) |
| 2026-08-13 | FDA approval | approved | BRISTOL MYERS SQUIBB BMY | ZENBEXUS | Approved 2026-08-13: ZENBEXUS (NDA221075 ORIG1) |
| 2026-04-09 | FDA approval | approved | BRISTOL BMY | ONUREG | Approved 2026-04-09: ONUREG (NDA214120 SUPPL3) |
| 2026-03-20 | FDA approval | approved | BRISTOL MYERS SQUIBB BMY | OPDIVO | Approved 2026-03-20: OPDIVO (BLA125554 SUPPL135) |
| 2026-03-06 | FDA approval | approved | BRISTOL BMY | SOTYKTU | Approved 2026-03-06: SOTYKTU (NDA214958 SUPPL2) |
| 2025-11-24 | FDA approval | approved | BRISTOL-MYERS SQUIBB BMY | OPDIVO QVANTIG | Approved 2025-11-24: OPDIVO QVANTIG (BLA761381 SUPPL5) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-18 est. | P3 | Bristol-Myers Squibb BMY | NCT05946941 A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | Sjögren's Syndrome | active not recruiting | 774 |
| 2026-11-02 est. | P3 | Bristol-Myers Squibb BMY | NCT06951711 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) | Bipolar Disorder Type I With Mania or Mania With Mixed Features | recruiting | 274 |
| 2026-11-01 est. | P3 | Bristol-Myers Squibb BMY | NCT06951698 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | Bipolar-I Disorder With Mania or Mania With Mixed Features | recruiting | 274 |
| 2026-10-19 est. | P3 | Bristol-Myers Squibb BMY | NCT05620407 A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | active not recruiting | 513 |
| 2026-10-19 est. | P3 | Bristol-Myers Squibb BMY | NCT05617677 A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | active not recruiting | 516 |
| 2026-10-12 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT05372354 A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refract | Multiple Myeloma | recruiting | 260 |
| 2026-10-06 est. | P3 | Bristol-Myers Squibb BMY | NCT06003426 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | active not recruiting | 1255 |
| 2026-09-30 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT05888831 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | Advanced Solid Tumors | active not recruiting | 100 |
| 2026-09-28 est. | P3 | Bristol-Myers Squibb BMY | NCT05552976 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relaps | Relapsed or Refractory Multiple Myeloma | active not recruiting | 606 |
| 2026-09-05 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT06730750 A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | Advanced Solid Tumors | active not recruiting | 360 |
| 2026-08-11 | P1/P2 | Bristol-Myers Squibb BMY | NCT06035497 A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas i | Relapsed or Refractory T-cell Lymphomas | active not recruiting | 83 |
| 2026-07-21 | P3 | Bristol-Myers Squibb BMY | NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis | Psoriasis | completed | 1466 |
| 2026-07-09 | P3 | Bristol-Myers Squibb BMY | NCT04039607 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | completed | 732 |
| 2026-05-27 | P3 | Bristol-Myers Squibb BMY | NCT03383458 A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Hepatocellular Carcinoma; Liver Cancer | active not recruiting | 545 |
| 2026-02-23 | P2 | Bristol-Myers Squibb BMY | NCT02719613 Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | Multiple Myeloma | completed | 67 |
| 2026-02-16 | P3 | Bristol-Myers Squibb BMY | NCT03661320 A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab | Urinary Bladder Neoplasms; Muscle-Invasive Bladder Cancer | completed | 855 |
| 2026-01-16 | P2/P3 | Bristol-Myers Squibb BMY | NCT03723655 A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM | Hypertrophic Cardiomyopathy; Obstructive Hypertrophic Cardiomyopathy; Non-obstructive Hypertrophic C | completed | 314 |
| 2025-12-03 | P1/P2 | Bristol-Myers Squibb BMY | NCT05255601 A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and | Lymphoma, Non-Hodgkin; Hodgkin Disease | terminated | 5 |
| 2025-11-25 | P3 | Bristol-Myers Squibb BMY | NCT06253221 A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Cardiomyopathy, Hypertrophic | active not recruiting | 44 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.